Navigation Links
George Institute receives Gates Foundation grant to survey funding flows
Date:3/20/2008

A team of international health experts is launching a major study to track global funding for research and development (R&D) for neglected diseases in developing countries by surveying global public, private and philanthropic investments. As funding for R&D for neglected diseases has increased, donors do not have a complete overview of how much is currently being spent and on what diseases, which makes determining funding gaps difficult. The George Institute for International Health received a 5 year $US8.8 million grant from the Bill & Melinda Gates Foundation to collect and report global investment into R&D for neglected diseases.

Too often, global health funders must base substantial R&D investment decisions on out-of-date, unreliable information. They lack information about how much or where to invest, or how their investments sit in the context of overall funding flows and priorities, said Dr Mary Moran, Project Leader at the George Institute. By providing an updated and in depth overview, we hope to help donors around the world determine where their investments are most needed, and prevent duplication of effort she added.

Annually for a five year period, The George Institute will survey and analyse public and private global funders, intermediaries and developers, collecting data through an online survey. The survey will examine all aspects of product R&D funding from basic research, through discovery and development, to post-registration activities that support product introduction. It will measure R&D investment into new drugs, vaccines, diagnostics, microbicides and other tools for tropical diseases such as malaria and sleeping sickness, as well as developing-country strains of global diseases such as pneumonia, meningitis and HIV/AIDS, which are often overlooked by product developers that typically prioritize industrialized country markets.

We hope that better information about global funding for R&D for neglected diseases will encourage new investments, and help ensure they are targeted for maximum impact, said Dr. Regina Rabinovich, Director of Infectious Diseases Development at the Gates Foundation.

The project maintains The George Institutes focus on delivering quality public health outcomes. The George Institute for International Health is a multinational not-for-profit research organisation with offices in Australia, China, India and the United Kingdom. The Institute works towards improvement and development of global health through undertaking high quality research, and applying this research to health policy and practice. Given its widely acknowledged work on neglected disease product pipelines and funding, the Health Policy Division of the George Institute is uniquely placed to deliver such an important and vital project.


'/>"/>

Contact: Emma Orpilla
eorpilla@thegeorgeinstitute.org
61-299-934-592
Research Australia
Source:Eurekalert

Related medicine news :

1. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
2. Live Webcast With President George H.W. Bush as Bono and DATA Are Honored With National Constitution Centers 2007 Liberty Medal in Historic Philadelphia
3. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
4. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
5. New USAID grant helps Georgetown meet unmet family planning needs worldwide
6. CNS Response, Inc. Appoints George C. Carpenter IV to Position of President
7. Reunion with patient inspires follow-up study on treatment for DiGeorge syndrome
8. Georgetown leads major effort to combat disparities in DC stroke care
9. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
10. George Harrison Fund for UNICEF Announces Donation for Bangladesh Cyclone Relief
11. DaVita Nurse Gives Keynote Speech to St. Georges Hospital Vascular Access Annual Meeting in London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: